beclometasone dipropionate + fluticasone furoate

The name **beclometasone dipropionate + fluticasone furoate** appears to be an erroneous expansion of the abbreviation **BDP + FF** found in Chiesi's respiratory pipeline. In clinical practice and Chiesi's documentation, **BDP + FF** refers to the fixed-dose combination of the inhaled corticosteroid (ICS) **beclometasone dipropionate** and the long-acting beta2-agonist (LABA) **formoterol fumarate**, marketed under brand names such as **Foster** and **Fostair**. Fluticasone furoate is a distinct inhaled corticosteroid, and a combination of two different corticosteroids is not a standard therapeutic regimen; no such product is currently approved or in clinical development. The intended Chiesi product (BDP/formoterol) is approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It is characterized by its extrafine formulation, which allows for high lung deposition in both large and small airways. Chiesi is also developing Carbon Minimal versions of this combination using the low-global-warming-potential propellant HFA 152a.